Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Hemostatic Disorders 1Agnosia 1

Interventions

Cyclophosphamide 2067Radiotherapy 1990Cisplatin 1856Carboplatin 1560Gemcitabine 1454Paclitaxel 1320Bevacizumab 1320pembrolizumab 1237Docetaxel 1227Oxaliplatin 1184Capecitabine 1176Fluorouracil 1083Dexamethasone 979Magnetic Resonance Spectroscopy 971Nivolumab 936Rituximab 929Drug Therapy 915Surveys and Questionnaires 898Doxorubicin 845Etoposide 843Radiosurgery 816Blood Specimen Collection 816Irinotecan 784Cytarabine 743fludarabine 726Leucovorin 684Surgical Procedures, Operative 639Lenalidomide 618Biopsy 594fludarabine phosphate 569

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Dipyrone × Clear all
NCT07384013 2026-02-03

Study Protocol: Impact of Metamizole (OptalginĀ®) on Anti-Xa Concentrations in Oncology Patients Receiving DOACs

Rambam Health Care Campus

Phase NA Recruiting
30 enrolled

Agnosia, Hemostatic Disorders

Data powered by HemOnc (CC BY 4.0) Colophon ⚔